XBIOTECH INC

Watch Xbiotech (XBIT) as its Vilamakitug phase‑II study hits key efficacy milestones, while the stock slides near a 52‑week low—stay tuned for regulatory updates.

Market snapshot: Xbiotech (XBIT) dips 5.66% at $2.02, amid a volatile biotech sector, but its strong antibody pipeline and Phase‑I progress could keep upside on the horizon.